On September 13 IOME Bio organized the inauguration of its laboratories now established within the Paul Strauss Center, in the heart of Strasbourg. This was an opportunity for the Managing Director, Sarah Holland, to thank all the partners in the … Read More
HOME
Mission: IOME Bio aims to harness unique mechanistic insights to overcome resistance to checkpoint inhibitors and deliver meaningful benefits for cancer patients
SCIENCE
IOME Bio builds on foundational insights and IP from world-renowned immuno-oncology researchers, and has an exclusive option to licence new IP arising from ongoing sponsored research at Harvard
ABOUT US
We are a venture-backed Harvard spin-off pursuing novel immuno-oncology targets with first-in-class antibodies
Our foundational science was discovered by Arlene Sharpe and Dennis Kasper at Harvard, and Gordon Freeman at the Dana-Farber Cancer Institute
We are addressing resistance to PD-1 blockade through proprietary mechanistic insights
We are centrally located in the beautiful city of Strasbourg, embedded in a vibrant health innovation ecosystem.
OUR LATEST NEWS
The IOME Bio team will meet potential investors and partners at the following conferences
• RESI – Boston, Sep 21-23
• SACHS Associates – Basel, Sep 21-22
• BIO EUROPE – Leipzig, Oct 24-26
• J.P. Morgan – San Francisco, Jan 2023
… Read More